GRAIL (GRAL) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
28 Apr, 2026Voting matters and shareholder proposals
Election of Class II Directors, with nominees Sarah Krevans and Steven Mizell, to serve until the 2029 Annual Meeting of Stockholders and until successors are elected and qualified.
Ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Additional business may be addressed if properly brought before the meeting or any adjournment.
Board of directors and corporate governance
Board recommends voting in favor of the nominated directors and the ratification of the external auditor.
Audit committee and external auditor matters
Proposal to ratify Ernst & Young LLP as the independent registered public accounting firm for the upcoming fiscal year.
Partial view of Summaries dataset, powered by Quartr API
Latest events from GRAIL
- Q1 2026 delivered 50% test volume growth, higher revenue, and a narrowed net loss as FDA review advanced.GRAL
Q1 20267 May 2026 - Shareholders to vote on director elections and auditor ratification amid CEO transition and growth focus.GRAL
Proxy filing28 Apr 2026 - Q2 revenue rose 11% to $35.5M as Galleri test sales and clinical milestones drove growth.GRAL
Q2 202522 Apr 2026 - Validated MCED test accelerates growth, partnerships, and prepares for FDA approval.GRAL
Jefferies Global Healthcare Conference 202522 Apr 2026 - Revenue up 17% year-over-year, net loss narrows, and cash position strengthened by new funding.GRAL
Q4 202514 Apr 2026 - NHS-Galleri trial demonstrated significant stage IV cancer reduction and strong commercial growth.GRAL
TD Cowen 46th Annual Health Care Conference3 Mar 2026 - Q2 revenue up 43%, $1.42B impairment drives $1.59B loss; restructuring extends cash runway to 2028.GRAL
Q2 20242 Feb 2026 - Galleri's multi-cancer detection strategy is advancing with strong clinical data and streamlined operations.GRAL
Morgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026 - Q3 revenue up 38%, Galleri sales surged 52%, cash runway into 2028, losses narrowed.GRAL
Q3 202414 Jan 2026